YIH
PLX icon

Y-Intercept (HK)’s Protalix BioTherapeutics PLX Stock Holding History

Y-Intercept (HK)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,818
Closed -$35.4K – 1524
2024
Q4 		$35.4K Buy
+18,818
New +$26.6K ﹤0.01% 1122
2024
Q3 		– Sell
-158,259
Closed -$185K – 1692
2024
Q2 		$185K Buy
+158,259
New +$187K 0.01% 1191

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Y-Intercept (HK)'s PLX Position: Q1 2025 in Review

Y-Intercept (HK) sold out of Protalix BioTherapeutics (PLX) in Q1 2025, closing a stake of 18,818 shares — an estimated $35.4K sold.

Y-Intercept (HK) first reported a position in PLX in Q2 2024 and held it in 2 quarters. The position peaked at $185K in Q2 2024. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2025.

  • Y-Intercept (HK) reported no remaining Protalix BioTherapeutics position as of Q1 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 18,818 Protalix BioTherapeutics shares in Q1 2025, an estimated $35.4K.
  • Y-Intercept (HK) first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Protalix BioTherapeutics position peaked at $185K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2025.

Based on Y-Intercept (HK)'s 13F filing for Q1 2025, filed 6 May 2025.